ZA200509457B - Recombinant antibodies and framents recognising ganglioside N-glycolyl-GM3 and use thereof in the diagnosis and treatment of tumors. - Google Patents
Recombinant antibodies and framents recognising ganglioside N-glycolyl-GM3 and use thereof in the diagnosis and treatment of tumors. Download PDFInfo
- Publication number
- ZA200509457B ZA200509457B ZA200509457A ZA200509457A ZA200509457B ZA 200509457 B ZA200509457 B ZA 200509457B ZA 200509457 A ZA200509457 A ZA 200509457A ZA 200509457 A ZA200509457 A ZA 200509457A ZA 200509457 B ZA200509457 B ZA 200509457B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- antibody
- substance
- fragment
- chain
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 26
- 238000011282 treatment Methods 0.000 title claims description 22
- 150000002270 gangliosides Chemical class 0.000 title description 18
- 238000003745 diagnosis Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims description 47
- 241001529936 Murinae Species 0.000 claims description 45
- 241000282414 Homo sapiens Species 0.000 claims description 44
- 230000035772 mutation Effects 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 26
- 210000004408 hybridoma Anatomy 0.000 claims description 26
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 22
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 20
- 230000004807 localization Effects 0.000 claims description 19
- 238000001727 in vivo Methods 0.000 claims description 18
- 206010027476 Metastases Diseases 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims 24
- 201000010893 malignant breast melanoma Diseases 0.000 claims 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 32
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 32
- 239000000427 antigen Substances 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 238000010276 construction Methods 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 16
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 13
- 238000009739 binding Methods 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241000724791 Filamentous phage Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000001173 tumoral effect Effects 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 125000003047 N-acetyl group Chemical group 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- -1 GM3 ganglioside Chemical class 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 101150044441 PECAM1 gene Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000012233 TRIzol extraction Methods 0.000 description 1
- 101100244556 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) porC gene Proteins 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 101150110193 porG gene Proteins 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20030092A CU23403A1 (es) | 2003-04-23 | 2003-04-23 | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200509457B true ZA200509457B (en) | 2006-07-26 |
Family
ID=40261249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200509457A ZA200509457B (en) | 2003-04-23 | 2005-11-22 | Recombinant antibodies and framents recognising ganglioside N-glycolyl-GM3 and use thereof in the diagnosis and treatment of tumors. |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1623997B1 (es) |
| JP (1) | JP2006524194A (es) |
| KR (1) | KR20060006937A (es) |
| CN (2) | CN1809592A (es) |
| AR (1) | AR044076A1 (es) |
| AU (1) | AU2004232391B2 (es) |
| BR (1) | BRPI0409664A (es) |
| CA (1) | CA2523449C (es) |
| CL (1) | CL2004000843A1 (es) |
| CR (1) | CR8105A (es) |
| CU (1) | CU23403A1 (es) |
| EA (1) | EA008353B1 (es) |
| ES (1) | ES2535813T3 (es) |
| GE (1) | GEP20084476B (es) |
| HK (1) | HK1183492A1 (es) |
| HR (1) | HRP20050922A2 (es) |
| HU (1) | HUE025266T2 (es) |
| IL (1) | IL171541A (es) |
| LT (1) | LT5353B (es) |
| LV (1) | LV13427B (es) |
| MX (1) | MXPA05011368A (es) |
| MY (1) | MY144620A (es) |
| NZ (1) | NZ543345A (es) |
| PE (1) | PE20050422A1 (es) |
| PL (1) | PL1623997T3 (es) |
| RS (2) | RS20110319A3 (es) |
| SI (1) | SI1623997T1 (es) |
| TN (1) | TNSN05274A1 (es) |
| TW (1) | TWI343923B (es) |
| UY (1) | UY28289A1 (es) |
| WO (1) | WO2004094477A1 (es) |
| ZA (1) | ZA200509457B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ568033A (en) | 1998-11-27 | 2011-04-29 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
| NO345763B1 (no) | 2003-06-16 | 2021-07-19 | Celltech R&D Inc | Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering. |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| AU2011250920B2 (en) | 2010-05-14 | 2015-05-21 | Amgen Inc. | High concentration antibody formulations |
| AU2012223358A1 (en) | 2011-03-01 | 2013-09-05 | Amgen Inc. | Sclerostin and DKK-1 bispecific binding agents |
| SG193610A1 (en) | 2011-03-25 | 2013-11-29 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
| CA2842432C (en) | 2011-08-04 | 2022-10-04 | Amgen Inc. | Method for treating bone gap defects |
| CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
| BR112014016108A2 (pt) | 2011-12-28 | 2018-09-11 | Amgen Inc | método de tratamento de perda óssea alvelar |
| CU24120B1 (es) * | 2012-03-01 | 2015-08-27 | Ct De Inmunología Molecular | Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3 |
| AU2013285488B2 (en) | 2012-07-05 | 2018-03-22 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| EP3119423B1 (en) | 2014-03-15 | 2022-12-14 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| CN104651314B (zh) | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
| US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| MX2018008106A (es) | 2015-12-30 | 2019-03-14 | Novartis Ag | Terapias con celulas inmunoefectoras de una eficacia mejorada. |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
| JP2020506700A (ja) | 2017-01-31 | 2020-03-05 | ノバルティス アーゲー | 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療 |
| EP3700926A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
| EP3700933A1 (en) | 2017-10-25 | 2020-09-02 | Novartis AG | Antibodies targeting cd32b and methods of use thereof |
| CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
| MA52217A (fr) | 2018-03-30 | 2021-02-17 | Amgen Inc | Variants d'anticorps anti-c-terminal |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| KR102344948B1 (ko) * | 2018-09-03 | 2021-12-28 | 세종대학교산학협력단 | 인간 순수만능줄기세포에 특이적인 단일클론항체 n1-a4 |
| JP2022514315A (ja) | 2018-12-20 | 2022-02-10 | ノバルティス アーゲー | ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ |
| WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| CN110208409A (zh) * | 2019-06-05 | 2019-09-06 | 中国海洋大学 | 一种乳腺癌的生物标志物及其应用 |
| US20230056470A1 (en) | 2019-12-20 | 2023-02-23 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
| US20230141511A1 (en) | 2019-12-20 | 2023-05-11 | Ludwig Institute For Cancer Research Ltd | Car-t cell therapy targeting ngcgm3 |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2078539C (en) * | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| CN1211123C (zh) * | 1994-01-25 | 2005-07-20 | 雅典娜神经科学公司 | 抗白细胞粘附分子vla－4的人源化抗体 |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| AU717611B2 (en) | 1994-10-28 | 2000-03-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Tumor-specific antibody fragments, fusion proteins, and uses thereof |
| AU724856B2 (en) * | 1995-06-30 | 2000-10-05 | Mochida Pharmaceutical Co., Ltd. | Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| CU22731A1 (es) * | 1998-02-05 | 2002-02-28 | Centro Inmunologia Molecular | Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen |
-
2003
- 2003-04-23 CU CU20030092A patent/CU23403A1/es unknown
-
2004
- 2004-04-21 PE PE2004000397A patent/PE20050422A1/es not_active Application Discontinuation
- 2004-04-21 CL CL200400843A patent/CL2004000843A1/es unknown
- 2004-04-22 JP JP2006504218A patent/JP2006524194A/ja active Pending
- 2004-04-22 MX MXPA05011368A patent/MXPA05011368A/es active IP Right Grant
- 2004-04-22 WO PCT/CU2004/000006 patent/WO2004094477A1/es active IP Right Grant
- 2004-04-22 ES ES04728755.2T patent/ES2535813T3/es not_active Expired - Lifetime
- 2004-04-22 HU HUE04728755A patent/HUE025266T2/en unknown
- 2004-04-22 MY MYPI20041468A patent/MY144620A/en unknown
- 2004-04-22 CN CNA2004800174578A patent/CN1809592A/zh active Pending
- 2004-04-22 CN CN201210517262.6A patent/CN103012586B/zh not_active Expired - Fee Related
- 2004-04-22 NZ NZ543345A patent/NZ543345A/en not_active IP Right Cessation
- 2004-04-22 TW TW093111267A patent/TWI343923B/zh not_active IP Right Cessation
- 2004-04-22 EP EP04728755.2A patent/EP1623997B1/en not_active Expired - Lifetime
- 2004-04-22 GE GEAP20049062A patent/GEP20084476B/en unknown
- 2004-04-22 KR KR1020057020182A patent/KR20060006937A/ko not_active Application Discontinuation
- 2004-04-22 RS RS20110319A patent/RS20110319A3/en unknown
- 2004-04-22 SI SI200432242T patent/SI1623997T1/sl unknown
- 2004-04-22 RS YU20050795A patent/RS51853B/en unknown
- 2004-04-22 CA CA2523449A patent/CA2523449C/en not_active Expired - Lifetime
- 2004-04-22 EA EA200501653A patent/EA008353B1/ru not_active IP Right Cessation
- 2004-04-22 AU AU2004232391A patent/AU2004232391B2/en not_active Ceased
- 2004-04-22 PL PL04728755T patent/PL1623997T3/pl unknown
- 2004-04-22 BR BRPI0409664-9A patent/BRPI0409664A/pt not_active Application Discontinuation
- 2004-04-23 AR ARP040101389A patent/AR044076A1/es active IP Right Grant
- 2004-04-23 UY UY28289A patent/UY28289A1/es not_active Application Discontinuation
-
2005
- 2005-10-21 HR HR20050922A patent/HRP20050922A2/xx not_active Application Discontinuation
- 2005-10-21 TN TNP2005000274A patent/TNSN05274A1/en unknown
- 2005-10-23 IL IL171541A patent/IL171541A/en active IP Right Grant
- 2005-11-21 LT LT2005101A patent/LT5353B/lt not_active IP Right Cessation
- 2005-11-22 LV LVP-05-152A patent/LV13427B/en unknown
- 2005-11-22 ZA ZA200509457A patent/ZA200509457B/en unknown
- 2005-11-25 CR CR8105A patent/CR8105A/es not_active Application Discontinuation
-
2013
- 2013-09-19 HK HK13110760.2A patent/HK1183492A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1623997B1 (en) | Recombinant antibodies and fragments recognising ganglioside n-glycolyl-gm3 and use thereof in the diagnosis and treatment of tumours | |
| JP5844790B2 (ja) | 癌を治療するための、ｏ−アセチル化型のｇｄ２ガングリオシドに特異的なモノクローナル抗体を含む医薬組成物 | |
| KR100919617B1 (ko) | 강글리오사이드-관련 재조합 항체 및 종양의 진단 및치료에 있어서 이의 용도 | |
| CN109963591B (zh) | B7h3抗体-药物偶联物及其医药用途 | |
| TW200938629A (en) | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same | |
| EP3741777A1 (en) | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| ES2296952T3 (es) | Metodo para tratar el mieloma multiple. | |
| JP2020508658A (ja) | Ｔｉｍ−３抗体、その抗原結合断片、及びそれらの医学的使用 | |
| CN112500485A (zh) | 一种抗b7-h3抗体及其应用 | |
| JP2022539344A (ja) | 抗ｃｅａ抗体及びその応用 | |
| JP2022514693A (ja) | Ｍｕｃ１８に特異的な抗体 | |
| CN112513088A (zh) | 抗ox40抗体、其抗原结合片段及其医药用途 | |
| JP2022514786A (ja) | Ｍｕｃ１８に特異的な抗体 | |
| JP5933044B2 (ja) | ガングリオシドに対する二重特異性を有する組換え抗体及びこれらの使用 | |
| CN109776677A (zh) | 一种人源化抗il-13抗体及其制备方法和应用 | |
| CN115947855B (zh) | 抗cd24抗体的制备及其用途 | |
| MX2008000884A (es) | Anticuerpos anti-cd26 y metodos de uso de los mismos |